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Holding the Lid on HIV
John F. Anderson, MD
Recent articles in the news media report that the rate of HIV infection among injection drug users (IDUs) in British Columbia has dropped over the past two years. 1, 2 The prevailing expert opinion is that HIV disease among IDUs has reached the saturation point. However, this explanation is accompanied by dire warnings that the epidemic is not over. Figurative language is used to explain the decline, e.g., 'once you burn through the fuel…the number of new infections come[s] down,' and colourful flaming metaphors caution against complacency, e.g., 'a smoldering epidemic…that can easily blow up again. ' Missing from the reports are two key points. The first is a discussion about the level of HIV disease prevalence where saturation is thought to have occurred. The second is an examination of factors that may have reduced the rate of HIV infection and may, in fact, be 'keeping the lid on' and preventing it from 'blowing off. ' There must be an operational definition for the term 'saturation' embedded in the technical dialect of infectious disease epidemiology. In practical general language, however, saturation refers to a condition of equilibrium. Within the context of the HIV epidemic, experts explain that all those at risk have become infected and until a new pool of potential high-risk individuals becomes available, rates of new infection remain stable. Presumably, saturation can occur at different disease prevalence levels for different infectious diseases. The current estimate of the prevalence of hepatitis C infection among severely marginalized IDUs in Vancouver is close to 90%. 3 In some countries, the prevalence of HIV infection among IDUs has reached 50%. 4, 5 In New York City, the seroprevalence rate of HIV stabilized between 55 and 60% after a four-year period of rapid spread when the percentage of infected IDUs rose from approximately 20 to 50%. 6 The overall prevalence of HIV infection among IDUs in British Columbia is difficult to determine given that the absolute number of IDUs is unknown and not every IDU has been tested. Unfortunately, the total number of IDUs tested is also unknown. Therefore, even the prevalence of HIV infection among tested IDUs is only an estimate. What we do know is that nearly 9,500 individuals in our province have tested HIV positive since 1985 and about 2,000 of these persons are IDUs. 7 If an additional 2,000 untested IDUs are also HIV positive, it is quite probable that around 25% of the IDUs in the province are infected with HIV disease, an estimate consistent with the findings of the Vancouver Injection Drug User Study (VIDUS). 8 This begs the following questions: After almost a decade of rampant spread, why isn't the overall prevalence of HIV disease among IDUs higher and why is the rate of new infections decreasing now? I would argue that one treatment intervention in particular -methadone maintenance -has influenced the course of the epidemic and the impact is reflected in both the overall disease prevalence and the decreasing rate of new infections.
In the early years of this decade, policymakers in British Columbia made a conscious decision to expand access to methadone maintenance treatment (MMT) in response to an increasing body of scientific literature supporting the effectiveness of MMT in reducing mortality and morbidity associated with injection drug use. Among the published studies were papers reporting extremely low rates of HIV infection among IDUs living in North America and Europe enrolled in MMT. [9] [10] [11] These findings compelled provincial leaders to increase the number of methadone treatment slots in British Columbia from less than 1,500 to more than 4,000. This strategy -a sound idea, backed by evidence -was supplemented with management methods. Methadone remained the most regulated prescription narcotic in Canada and both methadone prescribers and dispensers continued to be closely scrutinized.
What is interesting is that, despite the inevitable growing pains of expanding MMT within the complex environment of universal health care services, the health outcomes have been largely favourable and consistent with the research literature. Methadone diversion does occur. However, the number of illicit drug deaths related to methadone has remained low despite a three-to fourfold increase in the methadone program. What is even more striking is the impact MMT has probably had on the prevention of HIV infections among IDUs in British Columbia. A recent study conducted in New York City has found that duration and dosage of MMT influences HIV seroprevalence independent of other risk factors, e.g., year of last cocaine injection, needle sharing in shooting galleries, number of IDU sex partners, low income and ethnicity. 12 The same study also reports a low rate of incident infection of 1.7 per 100 person years at risk (PYAR) for MMT patients. In British Columbia, of the first 1,006 participants enrolled in the VIDUS in 1996 -a cohort of actively injecting and severely marginalized IDUs -119 self-reported as currently receiving MMT. The HIV seroprevalence in the portion of this subgroup enrolled in MMT for 2 years or greater was 14.6% compared to a baseline seroprevalence for the entire VIDUS cohort of 23.2%. The average rate of incident infection for untreated IDUs in British Columbia over the past five years is estimated at 6.0 per 100 PYAR. The subse-quent incidence of HIV infection among the subgroup of the VIDUS cohort that entered the study on MMT is not yet available but, based upon seroprevalence at baseline, it is reasonable to assume a rate between 1 and 2 per 100 PYAR for IDUs enrolled in MMT. Therefore, given that the number of IDUs receiving MMT in our province has increased substantially and continues to expand, the preventive impact of MMT on new HIV infection among IDUs is not inconsequential.
So, what about the future of the spread of HIV among IDUs? The epidemic is not over by any stretch of the imagination. New high-risk groups of IDUs are emerging whose behaviours affect other IDUs and other vulnerable populations. Attention must be directed at the underlying causes of the epidemic, such as poverty, discrimination and illiteracy. More research is needed to determine how to assist HIV-infected IDUs access antiretroviral therapy and other necessary services. We must, however, not lose sight of effective interventions, such as methadone treatment, that have helped contain the epidemic and improve the health of those IDUs with and without HIV disease.
Endiguer l'infection à VIH
John F. Anderson, MD
Selon de récents articles parus dans les médias, le taux d'infection à VIH chez les usagers de drogues injectables (UDI) en Colombie-Britannique a baissé au cours des deux dernières années.
1,2 L'opinion qui domine chez les spécialistes est que l'infection à VIH chez les UDI a atteint un point de saturation. Toutefois, cette explication s'accompagne de sérieuses mises en garde comme quoi l'épidémie n'a pas disparu. On a volontiers recours au langage imagé pour expliquer cette baisse en disant par exemple « une fois passée la première vague, le nombre de nouveaux cas diminue », ou encore à des avertissements hauts en couleur sous forme de métaphores pour éviter de se reposer sur ses lauriers comme par exemple « une épidémie qui couve, tel un volcan éteint, peut toujours se réveiller. » Toutefois, il manque deux éléments essentiels à ces rapports. Premièrement, un débat sur le niveau de prévalence de l'infection à VIH auquel on estime qu'il y a saturation. Deuxièmement, un examen des facteurs qui ont pu faire diminuer le taux d'infection et pourraient en fait contenir ce taux et l'empêcher d'exploser.
Il nous faut une définition pratique du terme « saturation » tel qu'on le trouve consacré par la terminologie technique servant à décrire l'épidémiologie des maladies infectieuses. Dans le langage courant, le mot saturation fait référence à un état d'équilibre. Par rapport à l'épidémie de VIH, les spécialistes expliquent que toutes les personnes à risque ont été infectées et que, jusqu'à l'apparition d'un nouveau groupe potentiel d'individus à risque élevé, les taux de nouvelles infections vont demeurer stables. On suppose qu'il peut y avoir saturation à différents niveaux de pré-valence pour différentes maladies infectieuses. L'estimation actuelle de la préva-lence de l'hépatite C chez les UDI extrêmement marginalisés de Vancouver est de l'ordre d'environ 90 %. 3 Dans certains pays, la prévalence de l'infection à VIH chez les UDI a atteint 50 %. 4 
